Tocagen — Forte Biosciences — Investor Presentation (June 2025)
66 slides from Tocagen's investor presentation, Jun 23, 2025
Slide 1: Forte Biosciences June 2025
Exhibit 99.3 FORTE BIOSCIENCES FORTE BIOSCIENCES JUNE 2025 1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ¡ Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securitie
Slide 3: Clinical Stage FB-102
CLINICAL STAGE FB-102 • CD122 is a subunit of the intermediate affinity IL-2/IL-15 receptor expressed on NK and T cells and is a subunit of the high affinity IL-2 receptor expressed on Tregs • FB102 (Forte’s anti-CD122 antibody) is designed to mediate both the IL-2 and the IL- 15 induced proliferati
Slide 4: Forte Biosciences Overview
FORTE BIOSCIENCES OVERVIEW • Strong Board of Directors comprised of leaders in industry including: • Scott Brun, MD – Former head of Abbvie product development • David Gryska – Former CFO of Incyte and Celgene • Barbera Finck, MD – Led Enbrel development at Immunex and Humira biosimilar development
Slide 5: Experienced Management
EXPERIENCED MANAGEMENT Forte’s management has extensive experience in manufacturing, quality, regulatory and clinical development Paul Wagner, Ph.D. – CEO Tony Riley – Chief Financial Officer Chris Roenfeldt, PMP – Chief Operating Officer Barbara Finck, MD – Senior Medical Clinician 5
Slide 6: FB102 CD122 Antagonist Mechanism
FB102 CD122 ANTAGONIST MECHANISM 6
Slide 7: Clinical Stage FB102 Overview
CLINICAL STAGE FB102 OVERVIEW CD122 is a subunit of the intermediate affinity IL-2/IL- 15 receptor expressed on NK cells, certain T cell subtypes and is a subunit of the high affinity IL-2 receptor expressed on Tregs FB102 (Forte’s anti-CD122 antibody) is designed to mediate both the IL-2 and the IL
Slide 8: FB102 In Vitro Data
FB102 IN VITRO DATA 8
Slide 9: FB102 Inhibits CD4+ and CD8+ T Cell Proliferation
FB102 INHIBITS CD4+ AND CD8+ T CELL PROLIFERATION Fold Reduction Isotype/FB102 FB102 inhibits IL-2/IL-15 IL-2 4.1 signaling back to baseline IL-15 4.6 levels of the unstimulated cell only 9 IL2+Isotype IL2 Only IL2+FB102 IL15+Isotype IL15 IL15+FB102 Cells O l n y RLU (Cell Titer Glo)
Slide 10: FB102 Inhibits NK Cell Proliferation Back to Baseline Levels
FB102 INHIBITS NK CELL PROLIFERATION BACK TO BASELINE LEVELS Fold Reduction Isotype/FB102 IL-2 5.6 FB102 inhibits IL-2/IL-15 IL-15 7.8 signaling back to baseline levels of the unstimulated cell only 10 IL2+Isotype IL2 Only IL2+FB102 IL15+Isotype IL15 IL15+FB102 Cells Only RLU (Cell Titer Glo)
Slide 11: FB102 Does Not Inhibit Regulatory T Cell Proliferation
FB102 DOES NOT INHIBIT REGULATORY T CELL PROLIFERATION FB102 does not inhibit high affinity IL-2 signaling of Tregs In the absence of IL-2 stimulation, FB102 does not impact cell viability and is comparable to unstimulated cell 11 Treg IL2+CD3+Isotype Treg IL2+CD3 Treg L + D3 F 1 2 I 2 C + B 0 Treg
Slide 12: FB102 Inhibits IL-2 and IL-15 Induction of Cytokines
FB102 INHIBITS IL-2 AND IL-15 INDUCTION OF IL-6, TNF-ALPHA, IFN- GAMMA, AND CSF-1 WITH 3 DIFFERENT T CELL DONORS 150 CSF-1 100 50 0 12 Cell Only Donor06 I r L15 + FB102 Dono 06 IL2 + FB102 Donor06 IL2 + Isotype Donor06 IL15 + Isotype Donor06 Cell Only Donor55 I 5 L1 + FB102 Donor55 IL2 + FB102 Donor
Slide 13: FB102 Inhibits T Cell Activation in In Vitro Disease Model
FB102 INHIBITS IL-2/IL-15 CD4+ AND CD8+ T CELL ACTIVATION IN IN VITRO DISEASE MODEL CD4+ and CD8+ T cells were treated with IL2 for 24 hours then with IL15 for 24 hours, simulating disease activity in the presence or absence of FB102 FB102 provides nearly complete inhibition of T cell activation CD8
Slide 14: FB102: Broad Autoimmune Indication Potential
FB102: BROAD AUTOIMMUNE INDICATION POTENTIAL 14
Slide 15: Pipeline-in-a-Product Potential for FB102
ALIGNMENT OF DISEASE BIOLOGY AND MECHANISM FOR FB102 HIGHLIGHTS “PIPELINE-IN-A-PRODUCT” POTENTIAL FOR FB102 IN AUTOIMMUNE DISEASES WITH HIGH UNMET NEED Disease Species Outcome Reference Celiac disease Mouse Improved IL-15-induced PNAS, 2009 mucosal damage Vitiligo Mouse Enhanced repigmentation Sci T
Slide 16: Celiac Disease
CELIAC DISEASE 16
Slide 17: No Approved Therapies for Celiac Disease
NO APPROVED THERAPIES FOR CELIAC DISEASE; POTENTIAL FOR A SIGNIFICANT MARKET OPPORTUNITY ¡ Celiac disease is an autoimmune disease that’s triggered by consuming gluten and results in damage to the small intestine ¡ Symptom include diarrhea, fatigue, headaches, anemia, nausea, dermatitis herpetiformi
Slide 18: IL-2 and IL-15 in Celiac Disease
IL-2 AND IL-15 IN CELIAC DISEASE (CED) IL-2 ¡ Clear genetic basis for involvement of IL-2 in CeD ¡ Gluten-induced IL-2 production differentiates true CeD from non-gluten induced GI symptoms ¡ IL-2 strongly correlates with symptom severity and Serum IL-2 peaks within 4 hours after gluten exposure ¡ I
Slide 19: FB102 Blocks Gluten-Induced Intestinal Damage
FB102 BLOCKS GLUTEN-INDUCED INTESTINAL DAMAGE IN CELIAC SUBJECT BY BLOCKING IL-2 AND IL-15 ACTIVATION OF CD8+ T CELLS healthy epithelium damaged epithelium + CD8+ CD8 cells T cell IL-15 damage epithelium FB102 blocks IL-15 and IL-2 IL-2 Gluten APC with specific gluten + CD4 T cell peptide lamina pro
Slide 20: FB102 Blocks Both IL-2 and IL-15, Advantages Over Other Drugs
FB102 BLOCKS BOTH IL-2 AND IL-15, PROVIDING POTENTIAL ADVANTAGES OVER OTHER DRUGS BEING CLINICALLY INVESTIGATED FOR CELIAC DISEASE Immunomodulators Gluten Modification Immunotolerance Gut Healing Single targeting Multi targeting IMGX-003 CNP-101/TAK-101 IMU-856 IL-15 à CALY-002 CD122 (IL-2/IL-15)àFB
Slide 21: Celiac Disease Morphologic and Histological Measurements
CELIAC DISEASE MORPHOLOGIC AND HISTOLOGICAL MEASUREMENTS IN CELIAC DISEASE 21
Slide 22: Intraepithelial Lymphocytes Mediate Damage to Villi
INTRAEPITHELIAL LYMPHOCYTES ARE MEDIATORS OF DAMAGE TO VILLI IN CELIAC DISEASE • Intraepithelial lymphocyte (IELs) are CD3+T cells that infiltrate the villus upon gluten challenge in celiac disease leading to villus atrophy • IEL count is measured as a density of CD3+ T cells per 100 enterocytes • S
Slide 23: Villus Height to Crypt Depth Ratio (Vh:Cd)
VILLUS HEIGHT TO CRYPT DEPTH RATIO (VH:CD) • Villus height to crypt depth (Vh:Cd) ratio measures morphological damage due to IEL infiltration after gluten exposure in celiac disease • Vh:Cd ratio in patients with CeD is ~2.0-3.0 when the patients are on Gluten Free Diet Adelman DC, Am J Gastroentero
Slide 24: Composite Histological Scale for Celiac Disease
COMPOSITE HISTOLOGICAL SCALE FOR CELIAC DISEASE Findings: A composite scale VCIEL comprising individual subject values for Vh:Cd and IEL with equal weighting appears to offer better accuracy and statistical precision, particularly for population analysis in clinical trials, as well as potentially of
Slide 25: FB102 Phase 1b Celiac Disease Study
FB102 PHASE 1B CELIAC DISEASE STUDY 25
Slide 26: Celiac Disease Phase 1b Design
CELIAC DISEASE PHASE 1B DESIGN • 32 subjects were enrolled at 9 sites (AUS/NZ) • Randomized 3:1 to FB102 vs PBO (24:8) • Subjects received 3 of 4 doses of either FB102 (10mg/kg) or placebo then began 16 day gluten challenge (2g,4g, 8g for 14 days) th • 4 dose of either FB102 or placebo on day 22 • E
Slide 27: Baseline Demographics
BASELINE DEMOGRAPHICS Placebo FB102 Overall Parameter N=8 N=24 N=32 Age (Years) Mean 38.3 40.8 40.1 Female 5 (62.5%) 19 (79.2%) 24 (75.0%) Sex [n (%)] Male 3 (37.5%) 5 (20.8%) 8 (25.0%) Hispanic or Latino 0 0 0 Not Hispanic or Latino 7 (87.5%) 23 (95.8%) 30 (93.8%) Ethnicity [n (%)] Not Reported 1 (
Slide 28: FB102 Demonstrates Significant Benefit in Phase 1b Celiac Study
FB102 DEMONSTRATES SIGNIFICANT BENEFIT IN PHASE 1B CELIAC DISEASE STUDY 28
Slide 29: FB102 Demonstrates Significant Composite Histology (VCIEL) Benefit
FB102 DEMONSTRATES STATISTICALLY SIGNIFICANT COMPOSITE HISTOLOGY (VCIEL) BENEFIT COMPARED TO PLACEBO Day 32 vs baseline VCIEL composite score –1.849 for PBO compared to 0.079 for FB102 treated subjects (p=0.0099) 29
Slide 30: FB102 Significant Difference in Change in IEL Density
FB102 DEMONSTRATES STATISTICALLY SIGNIFICANT DIFFERENCE IN CHANGE IN IEL DENSITY COMPARED TO PLACEBO Day 32 vs baseline mean IEL density increase of 13.3 for PBO compared to a decrease of 1.5 for FB102 treated subjects (p=0.0035) 30
Slide 31: Vh:Cd Ratio Improvement for FB102 vs Placebo
VH:CD RATIO IMPROVEMENT OBSERVED FOR FB102 VS PLACEBO Day 32 vs baseline Vh:Cd ratio improvement of 73% for FB102 (-0.046) compared to PBO (-0.173) 31
Slide 32: FB102 Gluten Challenge Symptom Benefit vs Placebo
FB102 DEMONSTRATED GLUTEN CHALLENGE SYMPTOM EVENT BENEFIT VS PLACEBO Gluten challenge (GC) symptoms reported in patient diaries/AE collection GC induced GI symptoms tracked: nausea, diarrhea, vomiting, abdominal pain, abdominal bloating Through the 16 day gluten challenge FB102 demonstrated a 42% sy
Slide 33: FB102 Phase 1b Celiac Disease Study Safety Summary
FB102 PHASE 1B CELIAC DISEASE STUDY SAFETY SUMMARY 33
Slide 34: FB102 Generally Safe and Well Tolerated: Adverse Events by Grade
FB102 GENERALLY SAFE AND WELL TOLERATED Treatment Emergent Adverse Events By Grade Placebo (N=8) FB102 (N=24) Overall (N=32) n (Participant n (Participant n (Participant % % % Count) Count) Count) All Any Grade 8 100.0% 23 95.8% 31 96.9% Grade 1 (Mild) 8 100.0% 22 91.7% 30 93.8% Grade 2 (Moderate) 6
Slide 35: FB102 Generally Safe and Well Tolerated: Adverse Events by Organ Class
FB102 GENERALLY SAFE AND WELL TOLERATED Treatment Emergent Adverse Events By Organ Class Placebo (N=8) FB102 (N=24) Overall (N=32) n (Participant n (Participant n (Participant System Organ Class Summary % % % Count) Count) Count) Participants with at least one TEAE 8 100.0% 23 95.8% 31 96.9% Gastroi
Slide 36: Celiac Disease FB102 Phase 2 Trial Overview
CELIAC DISEASE FB102 PHASE 2 TRIAL OVERVIEW 36
Slide 37: Celiac Disease Phase 2 Design
CELIAC DISEASE PHASE 2 DESIGN • 14 sites AUS/NZ initially • Initiation in 2H25 • US IND expected late 2025/early 2026 • Topline data readout expected in 2026 37
Slide 38: Vitiligo
VITILIGO 38
Slide 39: Large Unmet Need in Vitiligo
LARGE UNMET NEED IN VITILIGO PRESENTS A SUBSTANTIAL MARKET OPPORTUNITY ¡ Vitiligo is an autoimmune disease of the skin driven by pathogenic T cells that kill melanocytes and create white spots ¡ Vitiligo results in sensitive skin (increasing likelihood of sub burns), eye abnormalities, emotional cha
Slide 40: IL-15 Activation of Pathogenic CD8+ T Cells in Skin
IL-15 ACTIVATION OF PATHOGENIC CD8+ T CELLS IN SKIN Vitiligo patients have unpigmented skin due activated FB102 blocks activation of pathogenic T cells, restoring pathogenic T cells killing melanocytes melanocyte health and skin pigmentation Tokura Front Immunol. 2021 PMID 33633737 40
Slide 41: IL-2 Therapy Drives Vitiligo
IL-2 THERAPY DRIVES VITILIGO Enhanced Survival Associated with Vitiligo Expression during (1) Maintenance Biotherapy for Metastatic Melanoma 1 2 1 1 2 1 Peter D. Boasberg , Dave S.B. Hoon , Lawrence D. Piro , Maureen A. Martin , Akhide Fujimoto , Timothy S. Kristedja , 1 2 1 1 Sandeep Bhachu , Xing
Slide 42: Anti-CD122 Antibody Effective in Mouse Vitiligo Model
AN ANTI-CD122 ANTIBODY IS EFFECTIVE IN A MOUSE VITILIGO MODEL WITH ESTABLISHED DISEASE Repigmentation study Melanin-reactive T cells Melanin-reactive T cells eliminated pigment in tail eliminated pigment in tail Vehicle (control) treatment Anti-CD122 treatment did not restore pigment restored pigmen
Slide 43: Anti-CD122 in Mouse Vitiligo: Durable Response with Infrequent Dosing
ANTI-CD122 IN A MOUSE MODEL OF VITILIGO: POTENTIAL OF DURABLE RESPONSE WITH INFREQUENT DOSING REGIMEN Note: anti-mouse CD122 (surrogate molecule) was used in these studies. 43
Slide 44: FB102 Has a Unique MOA for Treating Vitiligo
FB102 HAS A UNIQUE MOA FOR TREATING VITILIGO BY INHIBITING TWO CYTOKINES TO REDUCE IMMUNE ATTACK OF MELANOCYTES Reducing Autoimmune Response JAK based Carries Black Box Warning Single Cytokine Multi Cytokine JAK 3/TEC à ritlecitinib (LITFULO) IL-17A à aixekizumab (Taltz), CD122 (IL-2/IL-15) à FB102
Slide 45: Vitiligo FB102 Trial Overview
VITILIGO FB102 TRIAL OVERVIEW 45
Slide 46: Vitiligo Phase 1b Design
VITILIGO PHASE 1B DESIGN • 10-12 sites in AUS/NA • Up to 32 subjects • F-VASI endpoint (16/24 weeks) • Topline data expected in 1H26 46
Slide 47: Alopecia Areata
ALOPECIA AREATA 47
Slide 48: Large Unmet Need in Alopecia Areata
LARGE UNMET NEED IN ALOPECIA AREATA PRESENTS A SIGINIFICANT MARKET OPPORTUNITY ¡ Alopecia areata is a common autoimmune disease that occurs when pathogenic T cells attack hair follicles causing hair loss ¡ Alopecia areata affects both men and women and affects all racial and ethnic groups ¡ Market O
Slide 49: Alopecia Areata Driven by T Lymphocytes Invading Hair Follicles
ALOPECIA ARETA (AA) IS DRIVEN BY T LYMPHOCYTES INVADING HAIR FOLLICLES ¡ A healthy hair bulb in anagen phase of the Left: Co-expression of hair follicle cycle is surrounded by an IL-15 and IL-15RA in alopecia areata (AA) but immunosuppressive environment (an not normal control immune privileged spac
Slide 50: FB102 Should Protect Hair Follicles from Immune Attack
FB102 SHOULD PROTECT HAIR FOLLICLES FROM IMMUNE ATTACK AFTER LOSS OF IMMUNE PRIVILEGE 50
Slide 51: Anti-CD122 or Anti-IL-2 Antibodies Prevent Hair Loss in Mouse Model
ANTI-CD122 OR ANTI-IL-2 ANTIBODIES PREVENT HAIR LOSS IN A MOUSE MODEL OF VITILIGO ¡ C3H/HeJ mice spontaneously alopecia with age with about 20% penetrance ¡ Grafting C3H/HeJ skin from a mouse with alopecia to mice that have not developed alopecia results in rapid disease onset (21 to 35 days) in 100
Slide 52: Competitive Pipeline
COMPETITIVE PIPELINE Reducing Autoimmune Response JAK based Carries Black Box Warning Single Target Multi Target JAK 3/TEC à ritlecitinib (LITFULO) S1P à etrasimod (VELSIPITY) CD122 (IL-2/IL-15) à FB102 JAK 1/2 à baricitinib (Olumiant) OX40 à IMG-007 IL-4/13 à dupilumab (Dupixent) JAK 1/2 à deuruxol
Slide 53: Type 1 Diabetes
TYPE 1 DIABETES 53
Slide 54: Type 1 Diabetes Caused by Autoreactive T Cells
TYPE 1 DIABETES IS CAUSED BY AUTOREACTIVE T CELLS DESTROYING INSULIN-PRODUCING PANCREATIC BETA CELLS ¡ Type 1 diabetes (T1D) is classified by three stages of progression ¡ Stage 1: at least one diabetes-related autoantibody but has normal blood sugar and no symptoms ¡ Stage 2: at least two diabetes-
Slide 55: Type 1 Diabetes Clinical Competitive Space
TYPE 1 DIABETES CLINICAL COMPETITIVE SPACE From TZIELD PI • The 2 approved products both carry significant challenges in their safety profile. • LANTIDRA • cell therapy that requires hospitalization for administration and cost $300K/cycle • 90% of subjects experience serious AEs • TZIELD • IV infusi
Slide 56: FB102 Inhibits IL-15/IL-2 Activation of Beta-Cell Specific CD8+ T Cells
BASED ON THE MOA, FB102 INHIBITS IL-15/IL-2 CYTOKINE FROM ACTIVATING BETA-CELL SPECIFIC CD8+ T CELLS, PREVENTING BETA-CELL KILLING IL-15/ FB102 blocks IL15RA IL-15 binding CD122/ CD132 CD8+ T cells with receptors recognizing Environmental stress causes β-cells to β-cell specific peptides are enriche
Slide 57: Single Anti-CD122 Injection Delays Diabetes Onset in NOD Mice
A SINGLE INJECTION OF ANTI-CD122 ANTIBODY DELAYS DIABETES ONSET IN NOD MICE AND ALSO KNOCKS DOWN NK CELLS Yuan 2018 JCI Insight PMID 29367461 57
Slide 58: FB102 Shows Significant Activity in In Vitro Models of Type 1 Diabetes
FB102 SHOWS SIGNIFICANT ACTIVITY: IN VITRO MODELS OF TYPE 1 DIABETES 58
Slide 59: FB102 Prevents Reactive T Cells from Proliferating
FB102 PREVENTS REACTIVE T CELLS FROM PROLIFERATING AND THEREFORE PREVENTING THE KILLING OF THE BETA CELLS • T cells antigen specific for Beta cells and Beta cells, both collected from T1D patients • T cells cultured with Beta cells in presence or absence of FB102 • FB102 inhibits the Beta cell induc
Slide 60: FB102 Inhibits Type 1 Diabetes T Cell Activation
FB-102 INHIBITS TYPE 1 DIABETES T CELL ACTIVATION FB102 inhibits T cells from T1D donor from being activated by beta cells. T1D T cells activated in the presence of Beta Cells as measured by an increase in CD69 levels and CD25 levels Activation of T cells is inhibited by FB102 but not by the (negati
Slide 61: FB102 Inhibits T1D T Cell Killing of Beta Cells
FB102 INHIBITS T1D T CELL KILLING OF BETA CELLS FB102 inhibits T cells from T1D donor killing of beta cells. FACS Analysis of Beta Cells with FB102 or Isotype Using T Cells from Type 1 Diabetes Patient – Beta Cell Killing Beta cell killing by T1D reactive T cells is inhibited by FB102 but not by the
Slide 62: Microscopy Shows FB102 Inhibition of T Cell Attack on Beta Cells
MICROSCOPY SHOWS FB102 INDUCED INHIBITION OF T CELLS ATTACK ON BETA CELLS D1417 + Beta Cells with FB102 D1417 + Beta Cells with Isotype Control T cells are NOT clustering to Beta Cells T cells are clustering to Beta Cells 62
Slide 63: Development Timelines
DEVELOPMENT TIMELINES 63
Slide 64: FB102 Proposed Clinical Development
FB102 PROPOSED 12 MONTH CLINICAL DEVELOPMENT Celiac Disease Vitiligo Phase 1b Phase1b Study Initiation 3Q24 Initiated 1H25 Positive Topline readout in June 2025 Topline data expected 1H26 Phase 2 Phase 2 Initiation 2H25 Initiation 2026 Topline data expected in 2026 Alopecia Areata Type 1 Diabetes Ph
Slide 65: Summary
SUMMARY 65
Slide 66: Clinical Stage FB-102
CLINICAL STAGE FB-102 • CD122 is a subunit of the intermediate affinity IL-2/IL-15 receptor expressed on NK and T cells and is a subunit of the high affinity IL-2 receptor expressed on Tregs • FB102 (Forte’s anti-CD122 antibody) is designed to mediate both the IL-2 and the IL- 15 induced proliferati
Forte Biosciences — Investor Presentation (June 2025) on 6ix